New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus daratumumab with or without pomalidomide showed progression-free survival of up to 81.3% and overall survival of up to 89.2% at 24 months1MonumenTAL-3 is the third positive study in recent months from Johnson & Johnson’s bispecific portfolio and is the first Phase 3 study of a GPRC5D bispecific investigational combination1,2,3 Results reinforce Johnson & Johnson’s leadership in multiple myeloma, advancing bispecific combinations earlier in the treatment journey, and expanding option